Garvan Institute of Medical Research

32 items matching your search terms.

Stromal cell diversity associated with immune evasion in human triple-negative breast cancer: Wu, S. Z.; Roden, D. L.; Wang, C.; Holliday, H.; Harvey, K.; Cazet, A. S.; Murphy, K. J.; Pereira, B.; Al-Eryani, G.; Bartonicek, N.; Hou, R.; Torpy, J. R.; Junankar, S.; Chan, C. L.; Lam, C. E.; Hui, M. N.; Gluch, L.; Beith, J.; Parker, A.; Robbins, E.; Segara, D.; Mak, C.; Cooper, C.; Warrier, S.; Forrest, A.; Powell, J.; O'Toole, S.; Cox, T. R.; Timpson, P.; Lim, E.; Liu, X. S.; Swarbrick, A.; EMBO JOURNAL 1 (39) :e104063, 2020 10.15252/embj.2019104063

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer: Portman, N.; Milioli, H. H.; Alexandrou, S.; Coulson, R.; Yong, A.; Fernandez, K. J.; Chia, K. M.; Halilovic, E.; Segara, D.; Parker, A.; Haupt, S.; Haupt, Y.; Tilley, W. D.; Swarbrick, A.; Caldon, C. E.; Lim, E.; BREAST CANCER RESEARCH 22 (1) :87, 2020 10.1186/s13058-020-01318-2

Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary: Grossmann, M.; Ramchand, S. K.; Milat, F.; Vincent, A.; Lim, E.; Kotowicz, M. A.; Hicks, J.; Teede, H. J.; MEDICAL JOURNAL OF AUSTRALIA 211 (5) :224-229, 2019 10.5694/mja2.50280

Estrogen receptor signaling is reprogrammed during breast tumorigenesis: Chi, D.; Singhal, H.; Li, L.; Xiao, T.; Liu, W.; Pun, M.; Jeselsohn, R.; He, H.; Lim, E.; Vadhi, R.; Rao, P.; Long, H.; Garber, J.; Brown, M.; PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 116 (23) :11437-11443, 2019 10.1073/pnas.1819155116

The International Academy of Cytology Yokohama system for reporting breast fine-needle aspiration biopsy cytopathology: Field, A. S.; Raymond, W. A.; Rickard, M.; Arnold, L.; Brachtel, E. F.; Chaiwun, B.; Chen, L.; Di Bonito, L.; Kurtycz, D. F. I.; Lee, A. H. S.; Lim, E.; Ljung, B. M.; Michelow, P.; Osamura, R. Y.; Pinamonti, M.; Sauer, T.; Segara, D.; Tse, G.; Vielh, P.; Chong, P. Y.; Schmitt, F.; ACTA CYTOL 63 (4) :257-273, 2019 10.1159/000499509

Immunoprofiling of breast cancer antigens using antibodies derived from local lymph nodes: Young, A. R.; Duarte, J. D. G.; Coulson, R.; O'Brien, M.; Deb, S.; Lopata, A.; Behren, A.; Mathivanan, S.; Lim, E.; Meeusen, E.; Cancers 11 (5) :682, 2019 10.3390/cancers11050682

Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer: Kennedy, S. P.; Han, J. Z. R.; Portman, N.; Nobis, M.; Hastings, J. F.; Murphy, K. J.; Latham, S. L.; Cadell, A. L.; Miladinovic, D.; Marriott, G. R.; O'Donnell, Y. E. I.; Shearer, R. F.; Williams, J. T.; Munoz, A. G.; Cox, T. R.; Watkins, D. N.; Saunders, D. N.; Timpson, P.; Lim, E.; Kolch, W.; Croucher, D. R.; BREAST CANCER RESEARCH 21 (1) :43, 2019 10.1186/s13058-019-1127-y

The proliferative and apoptotic landscape of basal-like breast cancer: Alexandrou, S.; George, S. M.; Ormandy, C. J.; Lim, E.; Oakes, S. R.; Caldon, C. E.; INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 20 (3) :667, 2019 10.3390/ijms20030667

The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis: Lee, K. W. C.; Lord, S.; Finn, R. S.; Lim, E.; Martin, A.; Loi, S.; Lynch, J.; Friedlander, M.; Lee, C. K.; BREAST CANCER RESEARCH AND TREATMENT 174 (1) :271-278, 2019 10.1007/s10549-018-5054-x

Non-canonical AR activity facilitates endocrine resistance in breast cancer: Chia, K.; Milioli, H.; Portman, N.; Laven-Law, G.; Coulson, R.; Yong, A.; Segara, D.; Parker, A.; Caldon, C. E.; Deng, N.; Swarbrick, A.; Tilley, W. D.; Hickey, T. E.; Lim, E.; ENDOCRINE-RELATED CANCER 26 (2) :251-264, 2019 10.1530/erc-18-0333

Overcoming CDK4/6 inhibitor resistance in ER positive breast cancer: Portman, N.; Alexandrou, S.; Carson, E.; Wang, S.; Lim, E.; Caldon, C. E.; ENDOCRINE-RELATED CANCER 26 :R15-R30, 2019 10.1530/erc-18-0317

Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm: Boyle, F.; Beith, J.; Burslem, K.; de Boer, R.; Hui, R.; Lim, E.; McCarthy, N.; Redfern, A.; Woodward, N.; Asia-Pacific Journal of Clinical Oncology 14 Suppl 4 :3-11, 2018 10.1111/ajco.13064

Emerging data and future directions for CDK4/6 inhibitor treatment of patients with hormone receptor positive HER2-non-amplified metastatic breast cancer: Lim, E.; Beith, J.; Boyle, F.; de Boer, R.; Hui, R.; McCarthy, N.; Redfern, A.; Wade, T.; Woodward, N.; Asia-Pacific Journal of Clinical Oncology 14 Suppl 4 :12-21, 2018 10.1111/ajco.13065

Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia: Grossmann, M.; Ramchand, S. K.; Milat, F.; Vincent, A.; Lim, E.; Kotowicz, M. A.; Hicks, J.; Teede, H.; CLINICAL ENDOCRINOLOGY 89 (3) :280-296, 2018 10.1111/cen.13735

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer: Cazet, A. S.; Hui, M. N.; Elsworth, B. L.; Wu, S. Z.; Roden, D.; Chan, C. L.; Skhinas, J. N.; Collot, R.; Yang, J.; Harvey, K.; Johan, M. Z.; Cooper, C.; Nair, R.; Herrmann, D.; McFarland, A.; Deng, N.; Ruiz-Borrego, M.; Rojo, F.; Trigo, J. M.; Bezares, S.; Caballero, R.; Lim, E.; Timpson, P.; O'Toole, S.; Watkins, D. N.; Cox, T. R.; Samuel, M. S.; Martin, M.; Swarbrick, A.; Nature Communications 9 (1) :2897, 2018 10.1038/s41467-018-05220-6